While acute hepatitis B infection is often resolved by the immune system, CHB occurs when the body's defences are unable to ...

Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class ...

Scientists from the Institut Pasteur, in collaboration with Kumamoto University in Japan, have assessed a new rapid ...

Chronic hepatitis B (CHB) is currently estimated to affect over 250 million people worldwide, and tenofovir disoproxil ...

Tenofovir disoproxil fumarate is currently the most widely used antiviral agent for chronic hepatitis B (CHB) treatment. Now, a new study has shown that switching to the drug besifovir leads to ...

Research published in JAMA Internal Medicine reveals statins may reduce liver cancer risk by 33% and liver complications by ...

People fully vaccinated against hepatitis B who are not immunocompromised can expect sustained immunity throughout their ...

Hepatitis B virus infection remains one of the leading causes of liver disease, including cirrhosis and hepatocellular carcinoma. Despite widespread vaccination and antiviral treatments, millions of ...

Broaden inclusion in research and guidelines. Regulatory agencies and funding bodies should require adequate representation ...

Interventions Identified to Eliminate Transmission of Hepatitis B in Africa Feb. 27 ... much as 2.4 times more likely to develop advanced liver ... Low-Level Traffic Air Pollution Linked to ...

Liver cancer, predominantly hepatocellular carcinoma (HCC), remains one of the most aggressive and leading causes of ...